Tyrosine kinase inhibitors in the first-line treatment for
metastatic nonclear cell renal carcinoma: A retrospective
analysis of a national database

J 2019

Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database

POPRACH, Alexandr, Kristína RUMANOVÁ, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Michal STANÍK et. al.

Basic information

Original name

Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database

Authors

POPRACH, Alexandr (203 Czech Republic, belonging to the institution), Kristína RUMANOVÁ (703 Slovakia, belonging to the institution), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution), Tomáš POKRIVČÁK (703 Slovakia, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Hana STUDENTOVA (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Jaroslav JURÁČEK (203 Czech Republic, belonging to the institution), Ondrej FIALA (203 Czech Republic), Jindrich KOPECKY (203 Czech Republic), Katerina KOPECKOVA (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic) and Tomáš BÜCHLER (203 Czech Republic)

Edition

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, New York, ELSEVIER SCIENCE INC. 2019, 1078-1439

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.882

RIV identification code

RIV/00216224:14110/19:00108580

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.urolonc.2018.12.017

UT WoS

000462158500019

Keywords in English

Nonclear cell renal carcinoma; Targeted therapy; Sunitinib; Pazopanib

Abstract

V originále

Background: Nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous group of primary kidney tumors. The aim of the present retrospective study was to analyze outcomes of patients with nccRCC treated with tyrosine-kinase inhibitors (TKIs) based on a national registry. Methods: The registry contained evaluable data of 93 nccRCC patients treated with first-line TKIs, including 87 patients with papillary renal cell carcinoma (RCC) and 6 patients with chromophobe RCC. The control cohort consisted of 1,788 patients with clear-cell RCC treated with firstline TKIs. Multivariable Cox proportional hazard model was used to evaluate the effect of potential prognostic factors on the survival measures. Results: Median progression-free survival was 11.8 and 6.5 months in the clear cell renal cell carcinoma and nccRCC patients, respectively (P = 0.018), and median overall survival was 33.2 and 22.0 months, respectively (P = 0.007). In the multivariate analysis, independent factors associated with inferior progression-free survival included high tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, and sunitinib (as opposed to pazopanib) as first-line targeted therapy. Independent predictors of inferior overall survival included nonclear cell histology, tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, older age, and sunitinib as first-line targeted therapy. Conclusions: The present retrospective, registry-based study confirms that patients with nccRCC treated with TKIs have worse clinical outcomes compared to clear cell renal cell carcinoma patients with similar baseline characteristics. (C) 2018 Elsevier Inc. All rights reserved.

Links

NV15-34678A, research and development project

Name: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

Citovat

POPRACH, Alexandr, Kristína RUMANOVÁ, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Michal STANÍK, Tomáš POKRIVČÁK, Igor KISS, Ondřej SLABÝ, Hana STUDENTOVA, Bohuslav MELICHAR, Jaroslav JURÁČEK, Ondrej FIALA, Jindrich KOPECKY, Katerina KOPECKOVA, Milada ZEMANOVA and Tomáš BÜCHLER. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2019, vol. 37, No 4, p. „294e1“-„294e8“, 8 pp. ISSN 1078-1439. Available from: https://dx.doi.org/10.1016/j.urolonc.2018.12.017.

@article{1612496,
   author = {Poprach, Alexandr and Rumanová, Kristína and Lakomý, Radek and Chloupková, Renata and Staník, Michal and Pokrivčák, Tomáš and Kiss, Igor and Slabý, Ondřej and Studentova, Hana and Melichar, Bohuslav and Juráček, Jaroslav and Fiala, Ondrej and Kopecky, Jindrich and Kopeckova, Katerina and Zemanova, Milada and Büchler, Tomáš},
   article_location = {New York},
   article_number = {4},
   doi = {http://dx.doi.org/10.1016/j.urolonc.2018.12.017},
   keywords = {Nonclear cell renal carcinoma; Targeted therapy; Sunitinib; Pazopanib},
   language = {eng},
   issn = {1078-1439},
   journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
   title = {Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database},
   url = {http://dx.doi.org/10.1016/j.urolonc.2018.12.017},
   volume = {37},
   year = {2019}
}

TY  - JOUR
ID  - 1612496
AU  - Poprach, Alexandr - Rumanová, Kristína - Lakomý, Radek - Chloupková, Renata - Staník, Michal - Pokrivčák, Tomáš - Kiss, Igor - Slabý, Ondřej - Studentova, Hana - Melichar, Bohuslav - Juráček, Jaroslav - Fiala, Ondrej - Kopecky, Jindrich - Kopeckova, Katerina - Zemanova, Milada - Büchler, Tomáš
PY  - 2019
TI  - Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
JF  - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL  - 37
IS  - 4
SP  - „294e1“-„294e8“
EP  - „294e1“-„294e8“
PB  - ELSEVIER SCIENCE INC.
SN  - 10781439
KW  - Nonclear cell renal carcinoma
KW  - Targeted therapy
KW  - Sunitinib
KW  - Pazopanib
UR  - http://dx.doi.org/10.1016/j.urolonc.2018.12.017
L2  - http://dx.doi.org/10.1016/j.urolonc.2018.12.017
N2  - Background: Nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous group of primary kidney tumors. The aim of the present retrospective study was to analyze outcomes of patients with nccRCC treated with tyrosine-kinase inhibitors (TKIs) based on a national registry. Methods: The registry contained evaluable data of 93 nccRCC patients treated with first-line TKIs, including 87 patients with papillary renal cell carcinoma (RCC) and 6 patients with chromophobe RCC. The control cohort consisted of 1,788 patients with clear-cell RCC treated with firstline TKIs. Multivariable Cox proportional hazard model was used to evaluate the effect of potential prognostic factors on the survival measures. Results: Median progression-free survival was 11.8 and 6.5 months in the clear cell renal cell carcinoma and nccRCC patients, respectively (P = 0.018), and median overall survival was 33.2 and 22.0 months, respectively (P = 0.007). In the multivariate analysis, independent factors associated with inferior progression-free survival included high tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, and sunitinib (as opposed to pazopanib) as first-line targeted therapy. Independent predictors of inferior overall survival included nonclear cell histology, tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, older age, and sunitinib as first-line targeted therapy. Conclusions: The present retrospective, registry-based study confirms that patients with nccRCC treated with TKIs have worse clinical outcomes compared to clear cell renal cell carcinoma patients with similar baseline characteristics. (C) 2018 Elsevier Inc. All rights reserved.
ER  -

POPRACH, Alexandr, Kristína RUMANOVÁ, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Michal STANÍK, Tomáš POKRIVČÁK, Igor KISS, Ondřej SLABÝ, Hana STUDENTOVA, Bohuslav MELICHAR, Jaroslav JURÁČEK, Ondrej FIALA, Jindrich KOPECKY, Katerina KOPECKOVA, Milada ZEMANOVA and Tomáš BÜCHLER. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2019, vol.~37, No~4, p.~„294e1“-„294e8“, 8 pp. ISSN~1078-1439. Available from: https://dx.doi.org/10.1016/j.urolonc.2018.12.017.

Detailed Information on Publication Record